GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Earnings Yield (Joel Greenblatt) %

Diamyd Medical AB (OSTO:DMYD B) Earnings Yield (Joel Greenblatt) % : -9.35% (As of Feb. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Earnings Yield (Joel Greenblatt) %?

Diamyd Medical AB's Enterprise Value for the quarter that ended in Feb. 2024 was kr1,262.39 Mil. Diamyd Medical AB's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was kr-118.10 Mil. Diamyd Medical AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Feb. 2024 was -9.35%.

The historical rank and industry rank for Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

OSTO:DMYD B' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5894.52   Med: -13.31   Max: 2924.42
Current: -12.42

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Diamyd Medical AB was 2924.42%. The lowest was -5894.52%. And the median was -13.31%.

OSTO:DMYD B's Earnings Yield (Joel Greenblatt) % is ranked better than
54.78% of 1411 companies
in the Biotechnology industry
Industry Median: -15.93 vs OSTO:DMYD B: -12.42

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Diamyd Medical AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Feb. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Diamyd Medical AB Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Earnings Yield (Joel Greenblatt) % Chart

Diamyd Medical AB Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.01 0.38 2.66 -10.73 -16.29

Diamyd Medical AB Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.81 -20.28 -16.29 -23.20 -9.35

Competitive Comparison of Diamyd Medical AB's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Diamyd Medical AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % falls into.



Diamyd Medical AB Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Diamyd Medical ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Aug. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-116.071/712.275717
=-16.30 %

Diamyd Medical AB's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-118.10 Mil.



Diamyd Medical AB  (OSTO:DMYD B) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Diamyd Medical AB Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB (OSTO:DMYD B) Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB (OSTO:DMYD B) Headlines

No Headlines